{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Du R"],"funding":["National Natural Science Foundation of China","the Doctoral Research Start-up Fund Project of Nanyang Institute of Technology","the Talent Program of Central China：Science and Technology Innovation Leading Talent","the Science and Technology Project of Henan Province"],"pagination":["9167"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11035576"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(1)"],"pubmed_abstract":["Syndecan-binding protein (SDCBP) was reported to stimulate the advancement of esophageal squamous cell carcinoma (ESCC) and could potentially be a target for ESCC treatment. There is a growing corpus of research on the anti-tumor effects of iron chelators; however, very few studies have addressed the involvement of dexrazoxane in cancer. In this study, structure-based virtual screening was employed to select drugs targeting SDCBP from the Food and Drug Administration (FDA)-approved drug databases. The sepharose 4B beads pull-down assay revealed that dexrazoxane targeted SDCBP by interacting with its PDZ1 domain. Additionally, dexrazoxane inhibited ESCC cell proliferation and anchorage-independent colony formation via SDCBP. ESCC cell apoptosis and G2 phase arrest were induced as measured b"],"journal":["Scientific reports"],"pubmed_title":["Dexrazoxane inhibits the growth of esophageal squamous cell carcinoma by attenuating SDCBP/MDA-9/syntenin-mediated EGFR-PI3K-Akt pathway activation."],"pmcid":["PMC11035576"],"funding_grant_id":["82273058","234200510006","NGBJ-2022-05","82002592","222102310156"],"pubmed_authors":["Xiao N","Du R","Guo K","Huang Y","Han L","Chen Z","Zhang H","Bian H","Li K","Zhou Z","Zhao X"],"additional_accession":[]},"is_claimable":false,"name":"Dexrazoxane inhibits the growth of esophageal squamous cell carcinoma by attenuating SDCBP/MDA-9/syntenin-mediated EGFR-PI3K-Akt pathway activation.","description":"Syndecan-binding protein (SDCBP) was reported to stimulate the advancement of esophageal squamous cell carcinoma (ESCC) and could potentially be a target for ESCC treatment. There is a growing corpus of research on the anti-tumor effects of iron chelators; however, very few studies have addressed the involvement of dexrazoxane in cancer. In this study, structure-based virtual screening was employed to select drugs targeting SDCBP from the Food and Drug Administration (FDA)-approved drug databases. The sepharose 4B beads pull-down assay revealed that dexrazoxane targeted SDCBP by interacting with its PDZ1 domain. Additionally, dexrazoxane inhibited ESCC cell proliferation and anchorage-independent colony formation via SDCBP. ESCC cell apoptosis and G2 phase arrest were induced as measured b","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-03T01:31:52.457Z","creation":"2026-04-22T03:13:24.615Z"},"accession":"S-EPMC11035576","cross_references":{"pubmed":["38649770"],"doi":["10.1038/s41598-024-59665-5"]}}